PRESS RELEASE – Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound

Dallas-Fort Worth (PRWEB) August 28, 2015 – Riordan-McKenna Institute founders, stem cell expert Neil Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies in Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound.

Before-After.262x175The case involved a 78-year-old male, who presented with a non-healing surgical wound following a right total knee replacement performed six weeks prior. The patient had not responded after 6 weeks of conservative wound care and the wound showed no signs of healing.

Dr. McKenna irrigated the wound in the operating room under pulse lavage and then placed two AlphaPATCH dry amniotic membranes (4 cm x 4 cm) over the wound before dressing it.

At the two-week follow-up visit, a central scab had formed. At four-weeks, the wound had completely scabbed over. At eight-weeks the scab had just fallen off and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.

The case report, entitled “Case Report Of Non-Healing Surgical Wound Treated With Dehydrated Amniotic Membrane” is published in the July issue of the Journal of Translational Medicine. Authors include Dr. Riordan, Dr. McKenna, Troy Chandler, PA-C, and Ben George, PA-C. This milestone in Dr. Riordan and Dr. McKenna’s ongoing study of biologic wound healing using amniotic tissue products and stem cells is the third peer reviewed journal article on regenerative medicine published by the Riordan McKenna Institute.

A common misconception is that dehydrated amniotic membrane products like AlphaPATCH contain live stem cells. Although dehydrated amniotic membrane does not contain any stem cells, it does contain a number of growth factors that promote healing and stimulate the body’s own stem cells to become activated and likely behave more similar to stem cells in a younger person.

“It’s gratifying to have this new tool in my toolbox. I treated conservatively and was getting nowhere. Even in a patient with a significant smoking history and decreased blood flow to his legs, we were able to achieve this result. Chronic wounds can be very frustrating for both the patient and the caregiver,” remarked Troy Chandler, PA-C, who participated in the patient’s treatment.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.

Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Stem cell treatment in Panama shows signs of hope for local Belle Fourche boy

By Karla J. Flack, Black Hills Pioneer

James Habeck and his mother Melissa

James Habeck and his mother Melissa

BELLE FOURCHE — Three-year old James Habeck and his family have returned from a medical trip to Panama. His mother Melissa Habeck said they are noticing signs of improvement as a result of the stem cell treatment James received at the Stem Cell Institute in Panama City, Panama.

Treatment is hoped to provide James with relief from some of the complications caused by his cerebral palsy and allow him to do things a toddler would normally be able to do such as talk, sit-up, walk, turn himself over in bed at night so he would have fewer sleeping issues, and use his hands and feet. Some with James’ condition have tight muscles, but James’ muscles are just limp.

Medical professionals told Melissa that the new stem cells would live actively in James for six months. During those six months of cell life, whatever James learns and the strength he gains should remain.

The Habecks returned to Belle Fourche June 7 and shortly thereafter James’ extensive line-up of therapy treatments began. He is on a fast track of learning and is currently undergoing speech, occupational, and physical therapies in both Rapid City and Belle Fourche.

This week he was fitted for a wheelchair and evaluated to see if an augmented and alternative communication device could help him communicate. If he can train his eyes to look at a particular item on the device his family will know what he is trying to communicate to them.

“They feel like he is stuck in his body, and that it is possible; he understands 75 percent of what I say to him,” Melissa said.
The Hebeck’s trip began May 31 and entailed an hour flight to Denver and six hours from Denver to Panama. James had never flown but he did well with the flights.

Melissa asked doctors why hospitals in the U.S. don’t offer the treatment James needs. The answer was FDA (Food and Drug Administration) regulations.

A Southlake, Texas, center recently opened. The extent of services offered is not being released at this time. [Note: This statement is not accurate. The Riordan-McKenna Institute in Southlake, Texas treats orthopedic conditions such as knee injuries and arthritis and rotator cuff injuries with a combination of bone marrow aspirate concentrate and AlphaGEMS amniotic membrane product. More information can be found at www.rmiclinic.com]

The Habecks met an athletic coach who was receiving stem cell treatment in Panama for multiple sclerosis. He said he was walking with a walker prior to his treatments. A filming crew was with him documenting his progress as he no longer has to use a walker after undergoing multiple stem cell treatments.

Melissa said staff at the Stem Cell Institute said a number of autistic patients come there for treatment. Heart failure, osteoarthritis, rheumatoid arthritis, spinal cord injury, and autoimmune diseases are also treated at the institute.
James had stem cells that were extracted from donated umbilical cords injected intravenously into his arms. The injections went fine some days but other days were problematic because his veins would rupture and the medical team would have to find a new vein. Melissa said by the end of the week both her and James were crying, but the staff was excellent in dealing with it.

“They were using a butterfly needle to access the veins but collapsing veins were still an issue and James was getting tired of getting poked with needles,” she said.

Melissa said she has been in contact with individuals who tried stem cell treatments that were not successful. She said people who had their own cells taken and then transferred back into their bodies told her their treatments were unsuccessful. She also said some who had gone to other countries and did the spinal stem cell procedures said those results weren’t positive. Melissa said she feels very positive about James’ treatment.

He has a special walker that he can use if someone pushes it for him.

“He took off by himself in his walker after treatment,” Melissa said.

He has also started trying to use his arms and legs to stabilize himself. He has more neck control and is trying to use his neck to raise his head. He has also shown improvement in efforts to gain eye contact with those who are talking to him. He has to fight for control as his eyes both stray separate ways.

Melissa said that when James was younger he tried to walk but then stopped trying; then he tried to sit. She was told that often times people with cerebral palsy have to abandon one thing to learn something else. Treatment will hopefully allow for a number of items to be learned and motor skills to be tackled simultaneously.

“He cried when they took the iPad from his sight on the plane and when the augmented and alternative communication device was taken from him,” Melissa said. This type of expression in connection with wanting something has not been something he was able to do in the past. She was happy he cried to have it back.

The Belle Fourche community rallied around the Habecks with a fundraiser March 22 wherein $20,000 was raised for James to have the stem cell treatment. Belle Fourche Police Chief Scott Jones and Belle Fourche Fire Chief Kip Marshall were taped to a building while raising funds and businesses donated door prizes. The Naja Shriners clowns helped raise funds Danielle Butler, James’ caregiver, organized the fundraiser. Many people joined together to help James. Melissa said she couldn’t believe it when it became possible for them to go for treatment.

Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

About Dr. Wade McKenna

Dr. Wade McKenna is cofounder of the Riordan-McKenna Institute. He is a leading advocate of Autologous Stem Cell Therapy and Regenerative Medicine focusing on advancing the clinical benefits in orthopedics.

Board certified in orthopedic surgery, Dr. McKenna is the chief medical officer and co-founder of Biologic Therapies, a product development and research company dedicated to the advancement of autologous adult stem cell therapy. His achievements include the recent development of the BioMac bone marrow aspiration catheter, treating world-class athletes, and developing numerous surgical and non-surgical stem cell application protocols.

After receiving his undergraduate degree and earning his medical degree at Oklahoma State University, Dr. McKenna completed his orthopedic residency at the Dallas/Ft Worth Medical Center and his trauma fellowship at Tampa General Hospital. With over 20 years in private practice, Dr. McKenna has successfully built McKenna Orthopedics in Trophy Club, Texas and North Central Texas Orthopedics & Sports Medicine in Decatur, Texas.

Dr. McKenna has a proven track record of producing positive clinical outcomes augmented by concentrated, autologous bone marrow aspirate. Dr. McKenna has applied this stem cell-enriched product to thousands of surgical and non-surgical patients. Successful applications include long bone non-unions; avascular necrosis of the femoral head; severe clavicle non-unions; cartilage regeneration; chondrogenesis and soft tissue repair of the shoulder; chronic tendonopathy; tendon ruptures; numerous applications to common, often difficult foot and ankle injuries; and wrists fractures.

Riordan-McKenna Institute
www.rmiclinic.com
801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

Stem Cells Used to Successfully Treat Chronic Achilles Tendon Injury

Ocala, FL, October 06, 2014 –(PR.com)-Biologic Therapies, Inc. (BTI), a company that specializes in the design and development of medical devices and procedures for the regenerative medicine market, announced today that its products have been used to successfully treat a chronically injured Achilles tendon with stem cell therapy.

A case report, titled ‘Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report’, was authored by Biologic Therapies’ Chief Medical Director, Dr. R. Wade McKenna, and Chief Scientific Officer, Dr. Neil H. Riordan, founders of the Riordan-McKenna Institute in Southlake, Texas, USA (www.rmiclinic.com).

The case involved a 56-year-old female patient complaining of a painful “knot” in her left Achilles tendon. The pain limited her ability to perform daily activities such as shopping or being up on her feet for longer than 30 minutes. She had been an active tennis player and recreational athlete, but had not been able to play tennis or jog for ten years. She reported significant pain when relaxing and great pain when walking. The patient had been to multiple physicians and had followed ten years of standard treatment with stretches and anti-inflammatories. She refused multiple offers of invasive surgery that could not promise a return to tennis.

On physical examination by Dr. R. Wade McKenna, the patient had a large, palpable knot in the Achilles tendon, very noticeable and acutely tender. An MRI scan showed severe hypertrophic changes with marked tendinopathy.

The patient received a point-of-care stem cell therapy treatment in Dr. McKenna’s office as an outpatient procedure using Biologic Therapies products. The physician drew bone marrow from her tibia (shin) bone, processed the marrow in a centrifuge to concentrate the stem cells and growth factors, then injected the stem cells and growth factors into and around her injured Achilles tendon. Prior to the injection of the concentrated stem cells and growth factors, an injection of local anesthesia was given to prevent pain. The patient reported little to no pain during or after the procedure.

After six weeks the patient reported no pain at rest and minimal pain while walking. After eight weeks, there was even less pain while walking. The knot was less than 50% of the pre-treatment size and was relatively non-tender to touch. She was back to playing tennis without significant pain or difficulty. After ten weeks the patient was doing much better. An MRI scan showed even more reduction in the size of the knot, and pain was reduced even further. After 32 weeks an MRI scan showed near complete healing of the treated Achilles tendon.

The case report has been published by the scientific journal, CELLR4, the Official Journal of The Cure Alliance. The report can be seen on the CELLR4 website at http://www.cellr4.org/article/1100.

According to Luke Whalen, Biologic Therapies’ CEO, “This is an extremely important development for Biologic Therapies. The case report shows that stem cell therapy is an effective treatment for chronic Achilles tendon injury, which has not been documented before. The report also shows that stem cell therapy for this type of injury can be administered in a physician’s office as a point-of-care outpatient procedure using Biologic Therapies products. There is no need for hospitalization and surgery as would have been the case previously.

“Another important aspect of the publication of this case report is that the scientific journal it was published by is one of the most prestigious publications in the regenerative medicine industry. The members of the CELLR4 Journal Editorial Board that reviewed and approved the report are literally the ‘who’s who’ of regenerative medicine professionals from around the world. We are honored that they chose to publish the report. This helps to reinforce Biologic Therapies’ position as a global leader in regenerative medicine,” said Whalen.

The CELLR4 Editorial Board is led by Editor in Chief, Camillo Ricordi
from the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA. Other editorial staff of note include the Associate Editor for Asia, Jianming Tan
of Fuzhou General Hospital, Xiamen University, China; Assistant Editor, Antonello Pileggi of the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA; and Assistant Board member Arnold I. Caplan
from Case Western Reserve University, Cleveland, Ohio, USA.

In the late 1980’s, Dr. Arnold Caplan and colleagues developed and patented the technology to isolate adult human mesenchymal stem cells (MSCs) from bone marrow and to preserve their multi-potency (Caplan et al., 2001; Koc et al., 1999; Lennon et al., 2006). Adult human MSCs are capable of differentiating into a number of tissue types including bone, cartilage, muscle, marrow, tendon, ligament, adipocytes, and connective tissue.

Over 100 scientists, physicians, researchers and educators from around the world make up the CELLR4 Editorial Board. A complete listing of the Board members can be found at http://www.cellr4.org/editorial-board

About CELLR4
CELLR4 (http://www.cellr4.org) is a scientific journal with particular focus on cellular repair, replacement, regeneration, reprogramming and differentiation. Its scope ranges from fundamental new discoveries in basic science to translational, clinical trials and delivery of novel therapeutic options. As the official journal of the international non-profit organization The Cure Alliance, CELLR4 serves as a platform for discussion of challenges and opportunities on the path to the development of new treatments, independently from the disease target. CELLR4 publishes commentaries and opinion papers on regulatory, legal, and ethical issues, as well as information on global collaborative platforms and funding opportunities of interest to the field.

CELLR4 also serves as the official journal of the Fondazione Cure Alliance Onlus, another non-profit international organization that include physicians, scientists, patients, patient advocates, business and philanthropy leaders, with the mission to promote collaborative efforts worldwide, while addressing and working to resolve impediments and challenges on the path to develop cures for diseases now afflicting humankind. In this direction, the publication serves as a shared communication platform to discuss challenges and opportunities on the path to develop new treatments.

About Biologic Therapies
Based in Ocala, Florida, Biologic Therapies, Inc. (www.biologictherapies.com), is a company with a principal strategy of seeking out and developing innovative, proprietary and patented technologies to meet the needs of the rapidly emerging science of regenerative medicine, including stem cell therapy. Biologic Therapies provides groundbreaking medical technologies that significantly enhance the body’s natural healing ability, thereby providing patients with improved outcomes and quicker restoration of function. The Company’s products provide access to the biologics / regenerative medicine sector of the healthcare market.